HR 6321
Lung Cancer Medicare Access to Precise Testing Act
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:36 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Lung Cancer Medicare Access to Precise Testing Act, aims to improve lung cancer treatment by requiring Medicare to cover biomarker testing. Biomarker testing analyzes a patient’s tissue or blood to identify specific characteristics of their cancer, which can help doctors choose the most effective treatment. The bill updates Medicare regulations to include this type of testing and ensures full payment for these tests.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.